Treatment of Type 2 diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?

A review on possible use Glucagon-like peptide-1 receptor drugs for Type 2 diabetes mellitus (T2DM) treatment

Authors

  • Smriti Sharma University of Delhi
  • Vinayak Bhatia ICARE Eye Hospital and Postgraduate Institute

Keywords:

Diabetes, treatment, Incretin, harmones, Diabetes drugs, Medicinal Chemistry

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic syndrome, which occurs due to increased glucose levels in the human body. There has been lot of work in developing novel approaches to tackle this disease. GLP-1 receptor (GLP-1R), one of the class-B G-protein-coupled receptors (GPCR), is a budding molecular target to design drugs for treating type 2 diabetes. In this review, authors have summarized the physiological actions of Glucagon-like peptide-1 receptor (GLP-1R) and current available drugs based on GLP-1 RAs. Some of the exemplary studies in this area have been examined in detail. Authors conclude that development of degradation-resistant, long-acting GLP-1 receptor agonists is a promising area of research and lot of work needs to be done to understand its mechanism of action.

Author Biography

Smriti Sharma, University of Delhi

Department of Chemistry, Miranda House, University of Delhi, India

GLP agonist diabetes

Published

2020-08-14

How to Cite

Sharma, S., & Bhatia, V. (2020). Treatment of Type 2 diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps? A review on possible use Glucagon-like peptide-1 receptor drugs for Type 2 diabetes mellitus (T2DM) treatment. Chemical Biology Letters, 7(4), 215-224. Retrieved from http://thesciencein.org/journal/index.php/cbl/article/view/114

Issue

Section

Review Articles